These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 9705950)
1. Protection against respiratory syncytial virus infection by DNA immunization. Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950 [TBL] [Abstract][Full Text] [Related]
2. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198 [TBL] [Abstract][Full Text] [Related]
3. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]
4. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323 [TBL] [Abstract][Full Text] [Related]
5. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. Schmidt AC; McAuliffe JM; Murphy BR; Collins PL J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329 [TBL] [Abstract][Full Text] [Related]
6. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge. Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602 [TBL] [Abstract][Full Text] [Related]
7. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385 [TBL] [Abstract][Full Text] [Related]
8. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590 [TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus F and G protein core fragments fused to HBsAg-binding protein (SBP) induce a Th1-dominant immune response without vaccine-enhanced disease. Khan IU; Ahmad F; Zhang S; Lu P; Wang J; Xie J; Zhu N Int Immunol; 2019 Mar; 31(4):199-209. PubMed ID: 30462215 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122 [TBL] [Abstract][Full Text] [Related]
11. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899 [TBL] [Abstract][Full Text] [Related]
12. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741 [TBL] [Abstract][Full Text] [Related]
13. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633 [TBL] [Abstract][Full Text] [Related]
14. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271 [TBL] [Abstract][Full Text] [Related]
15. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant. Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790 [TBL] [Abstract][Full Text] [Related]
16. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats. Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176 [TBL] [Abstract][Full Text] [Related]
17. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease. Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG J Virol; 2017 May; 91(10):. PubMed ID: 28250126 [TBL] [Abstract][Full Text] [Related]
18. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus. Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382 [TBL] [Abstract][Full Text] [Related]
19. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. Spender LC; Hussell T; Openshaw PJ J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139 [TBL] [Abstract][Full Text] [Related]
20. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zhang XJ; Zheng YB; Zheng YP; Hong T; He JS Int Immunopharmacol; 2017 May; 46():62-69. PubMed ID: 28259002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]